With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|The anti-tumor immune microenvironment in the Sonic Hedgehog subclass of medulloblastoma||Emory University / Anna Kenney, PhD||Innovation Grants||2019||Georgia|
|Role of the macro lncRNA KCNQ1OT1 in embryonal rhabdomyosarcoma tumorigenesis||Duke University / Corinne Linardic, MD/PhD||Innovation Grants||2019||North Carolina|
|Exploiting the Differentiation Potential of Pediatric High-Grade Glioma to Discover Novel Therapeutic Opportunities||Dana-Farber Cancer Institute / Mariella Filbin, MD/PhD||'A' Award Grants||2019||Massachusetts|
|Single-cell Atlas of Pediatric Osteosarcoma||Dana-Farber Cancer Institute / Natalie Collins, MD/PhD||Single-cell Pediatric Cancer Atlas Grant||2019||Massachusetts|
|Dissecting Microenvironmental Interactions in Pediatric High-Grade Gliomas that Promote Tumor Growth||Dana-Farber Cancer Institute / Mariella G. Filbin, MD/PhD||Crazy 8 Pilots||2019||Massachusetts|
|Selectively targeting EP300 with small molecules for neuroblastoma (NB) therapy||Dana-Farber Cancer Institute / Jun Qi, PhD||Innovation Grants||2019||Massachusetts|
|Epigenetic regulation of genomic instability and its therapeutic implications in T-cell acute lymphoblastic leukemia||Dana-Farber Cancer Institute / Birgit Knoechel, MD/PhD||Innovation Grants||2019||Massachusetts|
|Targeting symmetric division in pediatric cancers||Dana-Farber Cancer Institute / Rosalind Segal, MD/PhD||Innovation Grants||2019||Massachusetts|
|Platform development for target identification in high risk pediatric leukemias||Columbia University / Adolfo A Ferrando, MD/PhD, Charles Mullighan, MD||Crazy 8 Pilots||2019||New York|
|Using Splice Switching Oligonucleotides (SSOs) to target MDM2 for rhabdomyosarcoma therapy||Research Institute at Nationwide Children's Hospital / Dawn Chandler, PhD||Innovation Grants||2019||Ohio|